Testicular Choriocarcinoma 

Updated: Apr 04, 2017
Author: Michael B Williams, MD, MS; Chief Editor: Bradley Fields Schwartz, DO, FACS 


Practice Essentials

Testicular choriocarcinoma is one of the histologic types of nonseminomatous germ cell tumors (NSGCTs), which along with testicular seminoma constitute the two major histologic groups of testicular cancers. Pure choriocarcinoma of the testis is the exception to most of the rules established for testicular seminoma and all other forms of NSGCTs.

Like other germ cell tumors (GCTs), choriocarcinoma typically affects younger men. Unlike other such cancers, choriocarcinoma metastasizes hematogenously, with the testicular primary tumor often small or even "burned-out." In most reports, the tumor responds poorly to radiation and chemotherapy and carries a high mortality rate. Surgery is usually limited to radical orchiectomy for tissue diagnosis.[1]

For patient education information, see the Men's Health Center and Cancer Center, as well as Testicular Cancer and Testicular Self-Exam.

Pathophysiology and Etiology

Choriocarcinoma recapitulates placental tissue development. For unknown reasons, it metastasizes early via hematogenous routes to the lung, liver, and brain, among others.[1, 2]

Patients with a history of cryptorchidism are at a greatly increased risk of testis cancer (by a factor of 10-40 times). Abdominal undescended testis is associated with a greater risk than the inguinal form. An abdominal testis cancer is more likely to be seminoma, while a testis surgically brought to the scrotum via orchiopexy is more likely to be an NSGCT. Orchiopexy allows for earlier detection by physical examination but does not alter the risk of GCT. Ten percent of patients with a GCT have a history of cryptorchidism. In a series of 125 patients with a history or clinical evidence of cryptorchidism and testis tumor, 3 (2%) were pure choriocarcinoma, which is similar to the overall incidence of choriocarcinoma among GCTs.[3]

Genetic changes in the form of amplifications and deletions are observed predominantly in the 12p11.2-p12.1 chromosomal region. Gain of 12p sequences is associated with invasive growth of seminomas and nonseminomas. In contrast, spermatocytic seminoma shows a gain of chromosome 9, and most infantile yolk sac tumors and teratomas show no chromosomal changes.

Other risks include the following:

  • Testicular trauma

  • Mumps

  • Maternal estrogen exposure


United States

Testicular GCTs are rare, representing only 1%-2% of all malignancies in males and occurring in 1 of 250 men by age 65 years. However, these tumors represent the most common malignancy in men aged 15-35 years. The incidence rates are 3.7 cases and 0.9 cases per 100,000 per year in white males and black males, respectively. GCTs have several subtypes and frequencies, including seminoma (40%), embryonal tumor (25%), teratocarcinoma (25%), teratoma (5%), and choriocarcinoma (pure; 1%).


The incidence of testis cancer increased worldwide from the early 1960s to the mid 1980s. The malignancy is more common in whites than in nonwhites. The highest rates are in Denmark (8.4 cases per 100,000 per y) and Switzerland (6.2-8.8 cases per 100,000 per y), and the frequency varies across Europe. In a histologic review of 1010 orchiectomies from 1999 to 2011 from a single Mexican oncology institution, 0.6% were pure choriocarcinomas and 0.9% were mixed germ cell tumors with a predominant choriocarcinoma component.[4]



Ramon y Cajal et al (1987) reported a case of pure choriocarcinoma in the oldest patient recorded, aged 63 years.[5] The patient died of aspiration shortly after initiation of chemotherapy, so a determination of treatment efficacy in this age group was impossible. The second-oldest patient reported was aged 50 years.

In a literature review of 10,000 cases of germinal testicular cell tumors, Ramon y Cajal et al found 54 (0.5%) cases of pure choriocarcinoma. The tumors occurred most commonly in men aged 20-30 years.[5] In a 2008 review of 50 men older than 60 years with GCT, only one was found to have a component of choriocarcinoma.[6]




Unlike classic seminoma or mixed germ cell tumors (GCTs), pure choriocarcinoma is more likely to manifest as symptoms of metastatic disease and is the most common element observed in brain metastases. In male patients with metastatic foci from an unknown primary, the possibility of testicular choriocarcinoma should be kept in the differential diagnosis.[7]

The local tumor itself may be small and may not cause symptoms.


The local tumor in choriocarcinoma may be small or nonpalpable, whereas most testicular GCTs cause scrotal swelling and a palpable mass. Testicular pain, with or without radiating pain to the groin and abdomen, is possible but is more consistent with epididymitis.

Widely metastatic testicular GCTs, including choriocarcinoma, may also manifest as a "burned-out" local testis lesion that consists of fibrous scar with absent or minute amounts of viable tumor.

Physical examination findings from lung, liver, and/or brain metastases may be more pronounced than an abnormal finding on testicular examination.



Diagnostic Considerations

Other problems to be considered in the differential diagnosis include the following:

  • Chronic epididymitis

  • Non–germ cell testicular tumor, Leydig

  • Syphilitic gumma

Differential Diagnoses



Laboratory Studies

The workup for testicular choriocarcinoma should include assays of the following:

  • Alpha-fetoprotein (AFP)

  • Human chorionic gonadotropin, beta subunit (beta-hCG)

  • Liver function

AFP is secreted by yolk sac elements; elevated levels of AFP are consistent with NSGCT. Choriocarcinoma could be a component of such a tumor, but AFP is within the reference range in pure choriocarcinoma. AFP has a serum half-life of between 5 and 7 days.

Human chorionic gonadotropin is a glycoprotein with the same alpha unit as thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Therefore, the beta subunit must be assayed. Beta-hCG has a 24- to 36-hour half-life and is secreted by syncytiotrophoblast cells within the tumor. Beta-hCG levels are usually markedly elevated in pure choriocarcinoma. Persistently elevation of beta-hCG levels is defined as continued elevation of the tumor marker above the predicted levels based on serum half-life of 24-36 hours.[8] This can also be applied to AFP, in which levels above that expected for the zero order kinetics of a 5- to 7-day expected half-life represent persistent elevation. From a clinical perspective, persistent tumor marker elevation represents residual disease. As such, more advanced treatment modalities (eg, chemotherapeutic) may be required.

The liver enzyme profile should include lactate dehydrogenase (LDH). Elevated levels of LDH may indicate bulky or advanced disease; however, the sensitivity and specificity are limited compared with beta-hCG and AFP. Rising levels after treatment may indicate relapse. Elevation of the remaining liver function tests may correlate with metastatic liver disease.

Placental alkaline phosphatase (PLAP) levels are elevated in some patients with seminoma and advanced disease; however, smoking and several other tumors also cause elevations. Therefore, this marker not commonly used.

Recent research has identified a number of molecular biomarkers for testicular germ cell tumors, including microRNAs. In addition to diagnosis, these hold the potential for use in treatment selection and establishing prognosis.[9, 10]

Imaging Studies

Scrotal ultrasonography

Any male with a palpable testicular mass should undergo scrotal ultrasonography. Other indications for ultrasonography may include acute scrotal pain, hydrocele, or other nonspecific scrotal pain, swelling, or mass.

Choriocarcinoma is associated with hemorrhage and necrosis and may appear more cystic, inhomogeneous, and calcified than a seminoma.[11]

Abdominal CT scanning of the abdomen and pelvis with intravenous and oral contrast

In all other forms of testis GCT, CT scanning can be used to most commonly identify metastatic disease to the retroperitoneal lymph nodes, and it understages approximately 15%-20% of patients thought to have stage I.

In patients with pure choriocarcinoma, metastatic disease via hematogenous routes may skip the retroperitoneal lymphatics.

CT scanning of the brain

Choriocarcinoma is associated with brain metastases. In a review of 242 patients with metastatic germ cell testis cancer undergoing treatment with a multi-agent chemotherapy protocol, Vugrin et al (1979) found 38 cases of brain metastases.[12] Among patients with pure embryonal carcinomas, 13% had brain metastases, compared to 83% of patients with pure choriocarcinomas. Furthermore, choriocarcinomas tended to have multiple brain metastatic sites with cerebellar involvement.

In almost all cases, pulmonary metastases preceded or coincided with brain metastases.

Chest radiography/chest CT scanning

Chest CT scan is indicated only for an abnormal finding on chest radiography; however, choriocarcinoma has a high metastatic rate, and CT scanning of the chest is usually indicated.

Bone scan

In an autopsy study by Bredael et al (1982), GCTs had bony metastases at autopsy, including seminoma (56%), mixed choriocarcinoma (35%), teratocarcinoma (30%), and embryonal carcinoma (24%); however, 0 of 6 cases of pure choriocarcinoma metastasized to the bone.[13]

In pure choriocarcinoma, a bone scan can probably be omitted in the absence of bone pain.

Histologic Findings

Gross findings include a small hemorrhagic nodule with some grayish-white viable tumor at the periphery. Histology shows that choriocarcinoma contains both syncytiotrophoblastic cells and cytotrophoblastic cells in intimate association (see image below).

Testicular choriocarcinoma has multinucleated sync Testicular choriocarcinoma has multinucleated syncytiotrophoblastic cells that drape over smaller cytotrophoblastic cells, which together appear to form a border along a blood-filled villouslike space (upper right). Used with permission from Ernstoff MS, Heaney JA, and Peschel RE, eds. Testicular and Penile Cancer. Malden, Mass: Blackwell Science, Inc; 1998:20.

Syncytiotrophoblastic cells are responsible for beta-HCG production.


American Joint Committee on Cancer and the International Union Against Cancer staging systems are described below.[14] Additional staging systems are well discussed by Prow (1998).[15]

Primary tumor (T)

See the list below:

  • pTx - Primary tumor cannot be assessed

  • p0 - No evidence of primary tumor

  • pTis - Intratubular germ cell neoplasia

  • pT1 - Tumor limited to the testis and epididymis, no vascular/lymphatic invasion, may invade the tunica albuginea, no invasion of the tunica vaginalis

  • pT2 - Tumor limited to the testis and epididymis, vascular/lymphatic invasion or tumor extending through the tunica albuginea with involvement of the tunica vaginalis, invades beyond the tunica albuginea or into the epididymis

  • pT3 - Tumor invades the spermatic cord with or without vascular/lymphatic invasion.

  • pT4 - Tumor invades the scrotum with or without vascular/lymphatic invasion, invades the scrotum

Regional lymph nodes (N)


  • Nx - Nodes not assessed

  • N0 - No regional lymph node metastasis

  • N1 - Lymph node mass or multiple lymph node masses less than or equal to 2 cm in greatest dimension

  • N2 - Lymph node mass or multiple lymph node masses greater than 2 cm but less than or equal to 5 cm in greatest dimension

  • N3 - Lymph node mass greater than 5 cm in greatest dimension


  • pN0 - No evidence of tumor in lymph nodes

  • pN1 - Lymph node mass less than or equal to 2 cm in greatest dimension, 5 or fewer nodes positive

  • pN2 - Lymph node mass greater than 2 cm but less than 5 cm in greatest dimension, more than 5 nodes positive, evidence of extranodal extension of tumor

  • pN3 - Lymph node mass greater than 5 cm in greatest dimension

Distant metastases (M)

See the list below:

  • M0 - No evidence of distant metastases

  • M1a - Nonregional nodal or pulmonary metastases

  • M2b - Nonpulmonary visceral metastases

Table 1. Serum Tumor Markers (S) (Open Table in a new window)



HCG (mIU/mL)

AFP (ng/mL)


Not assessed

Not assessed

Not assessed








< 1.5 x N


< 5000


< 1000


1.5-10 x N






>10 x N





*N=upper limit of reference range for the LDH assay

Table 2. Stage Grouping (Open Table in a new window)

Stage grouping





Stage 0





Stage I





Stage IA





Stage IB





Stage IS

Any T




Stage II

Any T

Any N



Stage IIA

Any T




Stage IIB

Any T




Stage IIC

Any T




Stage III

Any T

Any N



Stage IIIA

Any T

Any N



Stage IIIB

Any T

Any N



Stage IIIC

Any T

Any N



Any T

Any N


Any S



Approach Considerations

The treatment of choriocarcinoma includes orchidectomy, chemotherapy, and retroperitoneal lymph node dissection.[7] High-dose chemotherapy with autologous stem cell rescue has been used in patients with incomplete responses to initial therapy.[16] A multimodal approach involving the urologist and hematologist/oncologist is essential in the treatment of advanced nonseminomatous germ cell tumors.

Medical Care

Metastatic nonseminomatous germ cell tumors (NSGCTs) are highly sensitive to cisplatin-based chemotherapy, with cure rates of approximately 80% for advanced disease and nearly 100% for early-stage disease. Furthermore, numerous randomized clinical trials conducted for NSGCT have identified effective chemotherapy regimens that reduce toxicity. Risk-adapted protocols are also available to tailor treatment regimens for patients with good, moderate, or poor risk factors.

Standard chemotherapy for good-to-poor–risk NSGCT is with bleomycin, etoposide, and cisplatin (BEP) for four cycles. Additional agents include vinblastine and ifosfamide.

Pure choriocarcinoma, an extremely rare variant comprising less than 1% of NSGCT cases, is not as sensitive to chemotherapy as mixed NSGCT. The authors' exhaustive search of major textbooks and the literature revealed no clear guidelines as to how to treat these patients. Most case reports describe patients presenting with advanced metastatic disease, with varying responses to chemotherapy. In general, standard chemotherapy for poor-risk NSGCT is the initial therapy. However, these patients may require salvage regimens and may benefit from referral to a major cancer center to be treated under protocols that can involve cyclical regimens or dose escalation with growth factor/stem cell support. Cases responsive to chemotherapy may require additional surgical debulking.

Further, as described by Logothetis et al (1986), choriocarcinoma syndrome entails hemorrhage from metastatic sites of choriocarcinoma corresponding with significant elevation of beta-hCG.[17] This clinical presentation, although rare, is life-threatening and requires immediate treatment.[18]

Surgical Care

Radical inguinal orchiectomy

Preoperative details are as follows:

  • Serum tumor markers must be drawn preoperatively because they fall rapidly postorchiectomy. Other staging tests can be performed preoperatively or postoperatively.

  • Because of the rapid doubling time of a potential choriocarcinoma, testis tumors are often scheduled for surgery rapidly to avoid upstaging.

  • Most patients with testicular choriocarcinoma are young and healthy and require only routine preoperative preparation.

  • Semen donation for subsequent fertility should be discussed if the contralateral testis function is in question; however, many patients with poor semen quality demonstrate improvement after orchiectomy.

  • Cosmetic testicular prostheses are readily available to interested patients. Coloplast, formerly Mentor, has an FDA-approved saline-filled testicular prosthesis that has been in use since 2002. This prosthesis can be placed at a later date, if desired, in an outpatient procedure. Bodiwala et al (2007) published an excellent review article on rationale and patient discussion.[19]

  • In a patient who presents with symptomatic metastatic lesions from a testis tumor, proceeding with platinum-based chemotherapy and delaying radical orchiectomy is reasonable. Radical orchiectomy is not a very morbid procedure but may delay the initiation of chemotherapy.

  • Differentiation of seminoma versus NSGCT for advanced disease is not important at the outset of treatment, as both groups receive the same regimen.

  • Although chemotherapy may result in disappearance of the testicular mass, orchiectomy is always indicated.

Intraoperative details are as follows:

  • Spinal, general, or (uncommonly) local anesthesia may be used. The inguinal area is shaved and prepared in standard fashion.

  • An inguinal incision is made to allow exposure of the external and internal iliac canal.

  • The external iliac fascia is opened, exposing the spermatic cord and the internal iliac canal. The spermatic cord is controlled with a Penrose drain in tourniquet fashion to stop retroperitoneal lymphatic and venous drainage of tumor cells.

  • The testis is then delivered from the scrotum, and the vas deferens and spermatic arteries are ligated separately.

  • A long nonabsorbable tie is left on the patient side of the spermatic cord to facilitate identification should retroperitoneal lymph node dissection become necessary, requiring dissection of the remaining spermatic cord structures from the abdominal exposure.

  • The external oblique fascia is reapproximated and the skin closed in standard fashion.

Postoperative details are as follows:

  • Radical orchiectomy is usually an outpatient procedure or is performed as a 23-hour admission, often accompanied by the staging workup.

  • As follow-up, patients are staged and referred for the appropriate adjuvant therapies.

Complications are rare but may include the following:

  • Wound infection

  • Inguinal skin numbness due to injury to the genitofemoral nerve

  • Hematoma

  • Standard anesthetic risks



Medication Summary

Metastatic pure choriocarcinoma is treated with the same multi-agent chemotherapy regimens used in nonseminomatous germ cell tumors (NSGCTs), which are discussed in a separate article (see Nonseminomatous Testicular Tumors).

Standard chemotherapy for poor-risk patients and some good-to-moderate–risk patients includes 4 cycles of BEP (ie, bleomycin, etoposide, cisplatin). Additional agents in some regimens or for salvage include vinblastine and ifosfamide.

Most case reports show a poor response to chemotherapy, and the literature offers no clear treatment guidelines.[5, 17, 20, 21, 22]

Antineoplastic agents

Class Summary

These agents inhibit cell growth and proliferation.

Bleomycin (Blenoxane)

Composed of cytotoxic glycopeptide antibiotics, which appear to inhibit DNA synthesis, with some evidence of RNA and protein synthesis inhibition to a lesser degree. Used in the management of several neoplasms as a palliative measure; however, it is an important part of curative regimens for testicular cancer.

Etoposide (Toposar, VePesid)

Arrests cells in the G2 portion of the cell cycle and induces DNA strand breaks by interacting with DNA topoisomerase II and forming free radicals.

Cisplatin (Platinol, Platinol-AQ)

Inorganic metal complex thought to act analogously to alkylating agents. Kills cells in all stages of cell cycle and inhibits DNA biosynthesis.

Ifosfamide (Ifex)

Related to nitrogen mustards and a synthetic analog of cyclophosphamide.

Vinblastine (Alkaban-AQ, Velban)

Alkaloid derivative that causes depolymerization of microtubules important to the mitotic spindle and cytoskeleton.



Further Outpatient Care

 As most cases of choriocarcinoma have poor risk features, primary chemotherapy is followed by radiographic reassessment and staging.

Further Inpatient Care

As outlined above, most radical orchiectomies are performed in the same day or in 23-hour observation settings. This surgery is comparable to an inguinal herniorrhaphy, and the patient can expect limited physical activity for a brief period following surgery.

Inpatient & Outpatient Medications

Following orchiectomy, a short course of pain management medication may be required.


Prior to diagnosis, testicular self-examination on a monthly basis should begin at puberty.

Following diagnosis of testicular carcinoma, a mutual understanding between the patient and his treating physician in terms of strict adherence to follow-up regimens must be discussed. Early on, the follow-up regimens are frequent, as tumors can dramatically advance within short periods.


In most reports, choriocarcinoma carries a dismal prognosis due to its early hematogenous spread. Examples are as follows:

  • Batata et al (1980) reported a 5-year survival rate of 0% (0 of 20 patients)[23]

  • Requena et al (1991) reported a case of pure choriocarcinoma with metastases to the skin (rare), lung, and brain; this patient was treated with a 4000-rad dose to the skull and a multi-agent chemotherapy regimen, including platinum, vinblastine, and bleomycin (PVB) and lomustine, VP-16, and VePesid; the patient's beta-hCG level normalized, and he was disease-free at 2 years[21]

  • Lepidini et al (1997) reported a patient treated with multi-agent chemotherapy who was disease-free at 43 months of follow-up[24]

  • In five cases of pure choriocarcinoma with brain metastases, all patients died, and median survival was 1 month despite treatment with multi-agent chemotherapy[12]

  • In a 9-year review of patients treated in multi-agent chemotherapy trials at Memorial Sloan-Kettering Cancer Center, Bosl et al (1983) reported five cases of pure choriocarcinoma and two long-term survivors[25]

  • A review of survival after a diagnosis of testicular germ cell cancers in Germany and the United States from 2002-2006 found that 5-year relative survival was lowest with choriocarcinomas: 80.1% in Germany and 79.6% in the US; this compared with survival rates of 93.3% and 91.0% with nonseminomas generally[26]

  • A review by Alvarado-Cabrero et al (2014) found that of six patients with pure testicular choriocarcinoma, all died of their disease after a median of 9.5 months; of eight patients with predominant choriocarcinoma, five died of the disease after a median of 27 months, one was alive with disease, and two were alive with no evidence of disease at 60 and 72 months of follow-up, respectively; the latter two patients were the only ones with M1a disease on presentation[4]